SCHEMBL7895100

SCHEMBL7895100

CCc1ccc(NC(=O)C2CCCCC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.67
RAB9A P51151 5/20 0.66
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
GAA P10253 1/20 0.64
TSHR P16473 1/20 0.64
NPC1 O15118 3/20 0.64
LMNA P02545 2/20 0.63
HPGD P15428 1/20 0.63
ENPP3 O14638 3/20 0.62
ENPP1 P22413 3/20 0.62
ENPP2 Q13822 2/20 0.62
MAPT P10636 2/20 0.58
CCR5 P51681 1/20 0.56
NAMPT P43490 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17843850 0.98 SMN1; SMN2 (0.68) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL9610938 0.92 KMT2A (0.74) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL13129131 0.87 LMNA (0.83) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL125695 0.86 PTPN1 (0.89) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL28656982 0.86 PTPN1 (0.89) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL13973509 0.85 POLB (0.67) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL10197817 0.84 KMT2A (0.61) SMN1; SMN2RAB9AMEN1KMT2ANPSR1
SCHEMBL17845335 0.84 MEN1 (0.61) SMN1; SMN2RAB9AMEN1KMT2ANPSR1
SCHEMBL22679393 0.83 POLB (0.69) PTPN1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL26351839 0.83 PTPN1 (0.62) PTPN1SMN1; SMN2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4198030-A1 IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF Shanghaitech University (CN) 2023-06-21 EP disclosed
WO-2022033548-A1 IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF 上海科技大学 2022-02-17 WO disclosed
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-20100273842-A1 AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF SHIONOGI & CO., LTD. (JP) 2010-10-28 US disclosed
US-20100267945-A1 AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2010-10-21 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed
EP-0898569-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GmbH (DE) 1999-03-03 EP disclosed
WO-1997040038-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GMBH (DE) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273842-A1 AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF NPY5R, NPY1R, NPY2R PTPN1 361/4885SMN1; SMN2 2304/4885RAB9A 3084/4885
US-20100267945-A1 AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY NPY5R, NPY1R, NPY2R PTPN1 405/4885SMN1; SMN2 1782/4885RAB9A 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.